Subhash Chnad Kheruka*, Anjali Jain, Naema Almaymani, Noura Makhmari, Khulood Al Riyami, Rashid ALSukaiti
January 29, 2024
DOI : 10.56831/PSSRP-03-083
The term "theranostics" has transcended its status as a mere buzzword in the realm of nuclear medicine, thanks largely to the groundbreaking advancements in prostate-specific membrane antigen (PSMA)–targeted radioligands. These radioligands, which can be labeled with either positron- or γ-emitting isotopes for imaging or with β- or α-emitting isotopes for therapy, have revolutionized prostate cancer management over the past decade. Their success has not only led to the rapid adoption of PSMA-targeted imaging and therapy as a new clinical standard but also inspired exploration into other diseases. This development begs the question: What makes PSMA theranostics so successful, and how can these principles be applied to other areas in nuclear medicine?.